These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 25061467)

  • 21. Thymoquinone attenuates oxidative stress of kidney mitochondria and exerts nephroprotective effects in oxonic acid-induced hyperuricemia rats.
    Dera AA; Rajagopalan P; Alfhili MA; Ahmed I; Chandramoorthy HC
    Biofactors; 2020 Mar; 46(2):292-300. PubMed ID: 31758843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal Effects of Hyperuricemia.
    Méndez Landa CE
    Contrib Nephrol; 2018; 192():8-16. PubMed ID: 29393089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Uric acid and chronic kidney disease: new understanding of an old problem.
    Kang DH; Chen W
    Semin Nephrol; 2011 Sep; 31(5):447-52. PubMed ID: 22000652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Friend or Foe? An Unrecognized Role of Uric Acid in Cancer Development and the Potential Anticancer Effects of Uric Acid-lowering Drugs.
    Mi S; Gong L; Sui Z
    J Cancer; 2020; 11(17):5236-5244. PubMed ID: 32742469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Uric acid as a link between renal dysfunction and both pro-inflammatory and prothrombotic state in patients with metabolic syndrome and coronary artery disease.
    Zapolski T; Waciński P; Kondracki B; Rychta E; Buraczyńska MJ; Wysokiński A
    Kardiol Pol; 2011; 69(4):319-26. PubMed ID: 21523662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hormonal and cytokine effects of uric acid.
    Sánchez-Lozada LG; Nakagawa T; Kang DH; Feig DI; Franco M; Johnson RJ; Herrera-Acosta J
    Curr Opin Nephrol Hypertens; 2006 Jan; 15(1):30-3. PubMed ID: 16340663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome.
    Baldwin W; McRae S; Marek G; Wymer D; Pannu V; Baylis C; Johnson RJ; Sautin YY
    Diabetes; 2011 Apr; 60(4):1258-69. PubMed ID: 21346177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uric acid: from a biological advantage to a potential danger. A focus on cardiovascular effects.
    Cortese F; Giordano P; Scicchitano P; Faienza MF; De Pergola G; Calculli G; Meliota G; Ciccone MM
    Vascul Pharmacol; 2019 Sep; 120():106565. PubMed ID: 31152976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hyperuricaemia and vascular risk: the debate continues.
    Landolfo M; Borghi C
    Curr Opin Cardiol; 2019 Jul; 34(4):399-405. PubMed ID: 30925517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allopurinol, rutin, and quercetin attenuate hyperuricemia and renal dysfunction in rats induced by fructose intake: renal organic ion transporter involvement.
    Hu QH; Wang C; Li JM; Zhang DM; Kong LD
    Am J Physiol Renal Physiol; 2009 Oct; 297(4):F1080-91. PubMed ID: 19605544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reactions of peroxynitrite with uric acid: formation of reactive intermediates, alkylated products and triuret, and in vivo production of triuret under conditions of oxidative stress.
    Gersch C; Palii SP; Imaram W; Kim KM; Karumanchi SA; Angerhofer A; Johnson RJ; Henderson GN
    Nucleosides Nucleotides Nucleic Acids; 2009 Feb; 28(2):118-49. PubMed ID: 19219741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Xanthine Oxidase and its Role as Target in Cardiovascular Disease: Cardiovascular Protection by Enzyme Inhibition?
    Schuchardt M; Herrmann J; Tolle M; van der Giet M
    Curr Pharm Des; 2017; 23(23):3391-3404. PubMed ID: 28413972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uric acid--a uremic toxin?
    Nakagawa T; Mazzali M; Kang DH; Sánchez-Lozada LG; Herrera-Acosta J; Johnson RJ
    Blood Purif; 2006; 24(1):67-70. PubMed ID: 16361844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Uric acid: a starring role in the intricate scenario of metabolic syndrome with cardio-renal damage?
    Stellato D; Morrone LF; Di Giorgio C; Gesualdo L
    Intern Emerg Med; 2012 Feb; 7(1):5-8. PubMed ID: 21842242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications.
    Puddu P; Puddu GM; Cravero E; Vizioli L; Muscari A
    J Cardiol; 2012 May; 59(3):235-42. PubMed ID: 22398104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyperuricemia and endothelial function: From molecular background to clinical perspectives.
    Maruhashi T; Hisatome I; Kihara Y; Higashi Y
    Atherosclerosis; 2018 Nov; 278():226-231. PubMed ID: 30326405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uric acid in metabolic syndrome: From an innocent bystander to a central player.
    Kanbay M; Jensen T; Solak Y; Le M; Roncal-Jimenez C; Rivard C; Lanaspa MA; Nakagawa T; Johnson RJ
    Eur J Intern Med; 2016 Apr; 29():3-8. PubMed ID: 26703429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study.
    Rodenbach KE; Schneider MF; Furth SL; Moxey-Mims MM; Mitsnefes MM; Weaver DJ; Warady BA; Schwartz GJ
    Am J Kidney Dis; 2015 Dec; 66(6):984-92. PubMed ID: 26209544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Why focus on uric acid?
    Johnson RJ
    Curr Med Res Opin; 2015; 31 Suppl 2():3-7. PubMed ID: 26414730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Uric acid and chronic kidney disease: which is chasing which?
    Johnson RJ; Nakagawa T; Jalal D; Sánchez-Lozada LG; Kang DH; Ritz E
    Nephrol Dial Transplant; 2013 Sep; 28(9):2221-8. PubMed ID: 23543594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.